Key result
Obesity in non-valvular cardiomyopathy is linked to longer hospital stays but not higher in-hospital mortality.
Why the study?
Does obesity influence early in-hospital outcomes and length of stay in patients with non-valvular cardiomyopathy?
Cohort (n=626)
No
Does obesity influence early in-hospital outcomes and length of stay in patients with non-valvular cardiomyopathy?
In patients with non-valvular cardiomyopathy, obesity is associated with a longer hospital stay but does not independently predict in-hospital mortality, reflecting a potential obesity paradox.
Answers are grounded in this paper and cite their sources.
Obesity was associated with longer stays but not mortality in non-valvular cardiomyopathy; hypothesis-generating for the obesity paradox, needing prospective confirmation.
30) and non-obese (BMI<30). Obese patients represented 37% (n=231) of our study population. The non-ischemic category of cardiomyopathy had a higher prevalence among the obese (35% vs 27%). A higher percentage of obese patients presented with heart failure (HF) symptoms rather than ischemia or arrhythmia (46%, 40%, and 7% for HF symptoms, ischemia, and arrhythmia, respectively). There was no significant difference in NVCM complications, including cardiogenic shock, pulmonary edema, and cardiac arrest, between the two groups. Obese patients had a significantly higher post-myocardial infarction (MI) ejection fraction (29.7±9.7 vs 27.5±9.7, p=0.01). We found a statistically significant positive correlation between BMI and length of in-hospital stay (P=0.04). In-hospital mortality was non-significantly different between our two groups, although numerically, it was higher among the non-obese group (obesity paradox) (10% vs 12%, p=0.2). Type of cardiomyopathy, cerebrovascular stroke, smoking, and sacubitril/valsartan intake were detected as independent predictors of in-hospital mortality among our patients. Conclusions Obesity among NVCM patients sets more burden on health facilities by the prolongation of the in-hospital stay of patients although BMI is not an independent predictor of death in those patients.
No takes yet. Share an insight, caveat, or question.
Shalaby et al. (2022) conducted a cohort in Non-valvular cardiomyopathy (n=626). Obesity (BMI ≥ 30) vs. Non-obese (BMI < 30) was evaluated on In-hospital mortality (p=0.254). Obesity in patients with non-valvular cardiomyopathy did not significantly affect in-hospital mortality (10% vs 12%, p=0.254) but significantly prolonged the length of hospital stay.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: